Summary. An isolated preparation from ovine placental extracts which was active in the rosette inhibition assay mimicking the activity of the so-called 'early pregnancy factor' (EPF) has been shown to contain a 12 kDa polypeptide which could be partially resolved from low-molecular-weight active moieties. N-terminal amino acid sequence analysis of the polypeptide indicated that it was ovine thioredoxin, an identification confirmed by isolation and complete sequence analysis of the corresponding cDNA. The cDNA for human thioredoxin was expressed in Escherichia coli and the recombinant protein isolated and purified. Pure recombinant thioredoxin alone did not induce the expression of increased rosette inhibition titres (RITs) when tested in the rosette inhibition assay; but, when tested in combination with cell stimuli such as pl atel et\x=req-\ activating factor (PAF) or serum, it allowed the expression of increased RITs where none was achieved in its absence. Thioredoxin acted in the assay to reverse a refractory state normally induced by these stimuli, allowing lipoxygenase-dependent moieties also induced by the stimuli to exert their effects, resulting in the expression of increased RITs. Antibodies to recombinant thioredoxin removed from pregnancy sera the capacity to induce increased RITs, i.e. to express EPF activity, thus establishing a role for thioredoxin or thioredoxin-like proteins and associated molecules in the mechanisms which allow pregnancy sera to induce increased RITs. Based on a consideration of these and other results, a new model for the study of the EPF phenomenon is presented and discussed.
Introduction
For 16 years the 'early pregnancy factor' phenomenon has defied molecular definition. First described in 1974 by Morton et al., this phenomenon is concerned with the detection in vitro of a lymphocyte-modifying activity in maternal serum. The activity is detected within hours of fertiliz¬ ation, being induced by the release of platelet-activating factor (PAF) from the fertilized ovum and is present for at least the first two-thirds of pregnancy, continued detection being dependent upon the presence of a viable embryo or fetus (Orozco et ai, 1986; Morton et al., 1987) . This most interesting activity with potential applications in early pregnancy testing, for monitoring fetal well-being and in the study of fertility control, is detected in the rosette inhibition assay. When lymphocytes are exposed to heterologous red blood cells in the presence of complement, a small subpopulation of the lymphocytes binds red blood cells to form rosettes. The ability of these lymphocytes to form rosettes can be inhibited in a dose-dependent manner by antilymphocyte serum (ALS), and so for a given ALS a rosette inhibition titre (RIT) may be defined. When lymphocytes are incubated in pregnancy sera prior to testing in this assay, an increased rosette inhibition titre is observed (Morton et al., 1976) . The ability of pregnancy sera to cause this increase has generally been ascribed (Morton et al., 1977 (Morton et al., , 1987 to the presence in these sera of a so-called 'early pregnancy factor' (EPF). Despite the common usage of this term, we emphasize here, as we have in the past (Clarke & Wilson, 1985) , that EPF is defined by an activity in a complex biological assay in vitro and it is likely that the molecular basis for the activity is multifactorial.
Notwithstanding this, and additional data indicating that a complex set of components may be involved Morton et ai, 1980) , many attempts have been made (Wilson et al., 1983; Cavanagh, 1984 Cavanagh, , 1985 Bose et al., 1989; Mehta et ai, 1989) to isolate EPF on the assumption that activity expression is due to the presence of a simple pregnancy-specific protein. Preparations have been reported from a number of sources with the polypeptide components displaying a variety of physicochemical properties. Common features have been the paucity of material isolated, restricted characterization and the lack of any convincing data linking specific molecules in the preparations to the events by which pregnancy sera induce increased RITs.
Recently, we (Clarke et ai, 1987) described a protocol for the isolation of a fraction from ovine placental extracts which was active in the rosette inhibition assay. The major protein component of the preparation was a 12 kDa polypeptide which tended to oxidize to form 25 kDa disulphidelinked dimers. Moreover, antibodies produced against this preparation removed all EPF activity not only from placental extracts but also from pregnancy sera. Here, we report the identification of the 12 kDa polypeptide as thioredoxin. The coding sequence for human thioredoxin has been iso¬ lated and expressed in Escherichia coli, enabling production of both wild type and mutant forms of the protein free of contaminants of eukaryotic origin. This has allowed us to establish a role for thioredoxin in the mechanisms which give rise to so-called EPF activity expression. In so doing, this work provides not only the first molecular information on the EPF mechanism but also a new model for the study of this phenomenon.
Materials and Methods
Analysis of the ovine placental preparation. A 200 pg sample of the ovine placental preparation of Clarke el ai (1987) was subjected to chromatography on a calibrated Bio Gel P30 column (0-9 92 cm) in 1m acetic acid, collect¬ ing fractions of 0-75 ml. Protein elution was monitored using the method of Krystal et ai (1985) . To facilitate analysis in the rosette inhibition assay, equal aliquots of fractions were pooled (see Fig. lb ), freeze-dried and resuspended in the original volume of phosphate-buffered saline (PBS). Samples of 1:10 serial dilutions prepared in PBS/bovine serum albumin (BSA) (0-1 mg/ml) were tested for their ability to cause an increase in RIT in the rosette inhibition assay. For analysis by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS PAGE), aliquants of selected fractions were freeze-dried and dissolved in SDS sample buffer lacking DL-dithiothreitol (DTT) . SDS PAGE was performed on 15% polyacrylamide gels and the gel subjected to silver staining as described by Clarke et al. (1987) .
Protein sequencing. Aliquants of the 25 kDa fraction from the Bio Gel P30 profile (see Fig. la ) containing 150 pmol of 25 kDa disulphide-linked dimer were subjected to TV-terminal amino acid sequence analysis using an Applied Biosystems Gas Phase Sequentor at the Brisbane Protein and Nucleic Acid Research Centre. The unique sequence shown in Fig. 2 was obtained with initial yields of TV-terminal amino acids of 280-300 pmol. Aliquants of the 12 kDa fraction (see Fig. la) were also subjected to analysis over 8 cycles.
Isolation of rat thioredoxin cDNA. Based on the amino acid sequence of the 12 kDa ovine placental protein, two oligonucleotide probes were designed:
(5'dGCGGCGTCCAGGGCCTCCTGGAAGGCGTACTTGGACTCGATCTGCTTCAC) and (5'dAAGAAGGGCTTGATCATCTTGCAGGGGCCGCACCAGGTGGCGGAGAAGTC) They corresponded to the noncoding strand sequence for amino acids 1-17 and 25-41, respectively (Fig. 2) and were end-labelled with 32 -and used to screen a rat liver cDNA library made in lambda gtlO. Hybridization was performed in 10% (w/v) dextran sulphate, lM-NaCl, 1% (w/v) SDS, 50mM Tris-HCl, pH 7-5, 5 Denhardt's and 500 pg denatured sonicated salmon sperm DNA/ml at 42°C overnight. The filters were then washed in 6 standard sodium citrate (SSC), 0-1 % SDS at 50°C. The 550 bp EcoRi insert from one positive phage was excised and subcloned into M13mpl8 and M13mpl9 for sequence analysis. Both strands were sequenced according to the dideoxy-chaintermination method of Sanger et al. (1977) .
Isolation ofhuman and ovine thioredoxin cDNAs. The 550 bp rat thioredoxin cDNA was used as a probe to screen a human liver cDNA library and an ovine adrenal cortex library. Hybridization was performed as above, but with the addition of 40% formamide; washing was carried out in 2 SSC, 0-1 % SDS at 42°C. The inserts from positive phage were subcloned and sequenced as described above.
Expression of the human thioredoxin cDNA in E. cob. A 600 bp fragment containing the human thioredoxin cDNA insert was subcloned into M13mp 19 and used for mutagenesis. A 30-base oligonucleotide (5'dACTCCAGCAGCCAC-CATGGTGAAGCAGATC) was synthesized and used to create an Ncol site containing the ATG sequence. Mutant phage were detected by hybridization to the 32P-labelled oligonucleotide after washing in 3-4m tetra methyl ammonium chloride (TMAC1) (Wood et ai, 1985) . After complete resequencing of the clone, the insert was excised and subcloned into the expression plasmid pET8.H3, under control of the T7 promoter. This construct was transformed into E. coli strain BL21[DE3], which contains the gene for T7 RNA polymerase under lac control (Studier & Moffatt, 1986 . After washing the Affi Gels 6 times with 002m sodium phosphate and 0-6M-NaCl, pH 7-4, and twice with 0-9% NaCl, the specifically bound material was eluted by resuspension of the gels in 0-4 ml of 0-5m acetic acid for 5 min with frequent vortexing. After centrifuga¬ tion the pH 2 eluates (test and control) were collected, freeze-dried and dissolved in 200 pi PBS/BSA and stored as aliquots at -30°C; 5 µ of 10-fold serial dilutions was taken of each fraction for testing in the rosette inhibition assay. Rosette inhibition assay. The assays were performed using mouse spleen cells using the modified, efficient protocol described previously (Orozco etai, 1986 (Orozco etai, , 1990 
Results
Characterization of the ovine placental preparation Two-dimensional gel electrophoresis analysis by Clarke et al. (1987) (Johnson et al., 1988) , rat (Tonissen et al., 1989) , chicken (Jones & Lund, 1988) , and E. coli (Holmgren, 1968) 1989) from a rat liver cDNA library. This insert was then used as a probe for screening a human liver cDNA library to isolate a human thioredoxin clone. The deduced amino acid sequence of one such human clone differed in two places (see Fig. 2 and legend) from the previously published sequence of Wollman et al. (1988) . Recombinant human thioredoxin was expressed in E. coli BL21 using a T7 RNA polymerase expression system. Human thioredoxin was produced as a soluble protein accounting for 15% of the total protein in induced cells and was purified to homogeneity using ion-exchange chromatography (Fig. 3a, b) .
Role of thioredoxin in the rosette inhibition assay Pure human recombinant thioredoxin was without activity in the rosette inhibition assay. When mouse spleen cells were incubated with this protein over a wide range of concentrations, the RITs determined were equivalent to those obtained after control incubations in PBS or nonpregnancy sera (Fig. 4a) . However, we found that, while thioredoxin and nonpregnancy sera individually do not cause the expression of increased rosette inhibition titres, the combination does. When thioredoxin and male mouse serum were simultaneously added to mouse spleen cells, increased RITs were observed, dose-response data (Fig. 4a, b) showing that thioredoxin was extremely effec¬ tive in co-operating with nonpregnancy serum components to induce activity expression. When mouse spleen cells were first incubated with male mouse serum alone, washed, then incubated with pure thioredoxin before testing, increased RITs were still observed over a comparable range of thioredoxin concentration (Fig. 4a) as when both were added simultaneously; but when, the twostep incubation was performed in reverse order, there was no change (Fig. 4a) in RITs above negative control values. This suggests that thioredoxin plays a permissive role subsequent to the action of serum components on the spleen cells and in this way the combination mimics the action of pregnancy serum ascribed to the so-called 'early pregnancy factor'.
The co-operation between thioredoxin and male mouse serum resembles our findings (Orozco et al., 1990 ) that a combination of oestrus-specific mouse serum components and PAF could also increase RITs. Neither alone was effective, the combination was required. Again the effect was observed in a two-step incubation protocol only when a prescribed order of addition was followed, in this case, PAF being applied in the first step. Extensive studies (Clarke et al., 1990a; Orozco et al., 1990) (Fig.  6) . Also, in two-step incubation protocols, increased RITs were observed only when PAF was added in the first step, followed by thioredoxin in the second (Fig. 6 ), indicating that thioredoxin was functionally equivalent to the oestrus-specific serum components (Orozco et al., 1990 ) by acting to reverse the PAF-induced refractory state. Fig. 6 . Dose-response effects of thioredoxin on the rosette inhibition titre (RIT) when tested in combination with 5nM platelet-activating factor (PAF) when both were added simultaneously (D), when PAF was added first in a two-step incubation protocol (·) and when thioredoxin was added first in a two-step protocol ( ). All data points are means of 3-4 determinations. samples with the pH 2 eluates from these adsorptions were then tested for their ability to co-operate with PAF in inducing increased RITs. As shown by the dose-response data (Fig. 7) , oestrous mouse serum (but no other non-pregnancy serum) could co-operate with PAF to induce increased RITs. This capacity was specifically removed by adsorption with anti-thioredoxin antibodies (Fig.  7a) and could be specifically recovered in the pH 2 eluates from such adsorptions, indicating that the components in oestrous mouse serum which act to reverse the PAF-induced refractory state were related to thioredoxin. None of the other non-pregnancy sera, their adsorbed supernatants, or pH 2 eluates (see Fig. 7a ) possessed the capacity to co-operate with PAF in inducing increased RITs, again indicating that this capacity (due, at least in part, to components related to or associ¬ ated with thioredoxin), was oestrus-dependent.
Involvement of thioredoxin-related proteins in the 'EPF' phenomenon A final series of experiments was performed to demonstrate the direct involvement ofthioredoxinrelated proteins in the EPF phenomenon. As EPF activity has been defined as the ability of pregnancy sera to induce increased rosette inhibition titres in the rosette inhibition assay, we asked whether specific anti-thioredoxin antibodies could specifically remove this capacity from pregnancy sera. The preparation of recombinant human thioredoxin, free from contamination by other vertebrate proteins, was used to generate specific antisera. The gammaglobulin fractions were isolated from selected immune and pre-immune sera and coupled to Affi-Gel for use as solid-phase adsorbents.
Extensive adsorption experiments performed with these reagents (see Fig. 7b ) revealed that (i) the ability of pregnancy sera to induce the expression of increased RITs was lost on adsorption with anti-thioredoxin antibodies; (ii) this ability could be recovered in the pH 2 eluates from the anti¬ thioredoxin adsorptions of pregnancy serum samples, but not from such adsorptions of non¬ pregnancy sera; (iii) the ability of anti-thioredoxin-adsorbed pregnancy sera to induce increased RITs could be restored by the addition of pure recombinant thioredoxin; and (iv) the ability to induce increased RITs could also be conferred on anti-thioredoxin-adsorbed samples of non¬ pregnancy serum by addition of thioredoxin.
Results (iii) and (iv) indicated that anti-thioredoxin antibody treatment of pregnancy and non¬ pregnancy sera did not remove the capacity of these sera to stimulate the production of S2 factors or the ability to render the stimulated cell population refractory to the action of these compounds. Thus, activity expression with these adsorbed sera, as with normal sera (Fig. 4a) by the addition of thioredoxin to the sample. The ability of these adsorbed sera to stimulate the production of an active S2 fraction could also be directly demonstrated (data not shown) as it was for non-adsorbed serum samples (Fig. 5a, b) .
Discussion
These studies have identified thioredoxin as the major polypeptide component in our ovine placental preparation (Clarke et al., 1987) which mimics the action of pregnancy sera by inducing the expression of increased rosette inhibition titres in the rosette inhibition assay. Pure thioredoxin produced by recombinant techniques was devoid of this activity, but could play a permissive role in this assay under certain circumstances. When pure thioredoxin was applied to spleen cells with or following appropriate cell stimuli such as PAF or sera, it resulted in an increased rosette inhibition titre where none was achieved in its absence. In general terms, it does this by preventing or revers¬ ing a refractory state induced in the spleen cells by these stimuli, allowing lipoxygenase-dependent products, also generated as a consequence of the stimulation, or naturally present in the sample in the case of serum, to exert their effects. The nature of the refractory state and the mechanistic detail of its reversal by thioredoxin are not known and are the subject of continued study. In these studies, site-directed mutagenesis techniques are being applied to examine whether the classical protein disulphide reducíase activity of thioredoxin (Holmgren, 1979 (Holmgren, , 1989 ) is directly involved. This is not the first report of isolated preparations having thioredoxin as the only or major polypeptide component and which display potent activity in biological assays. Tagaya et al. (1989) reported a thioredoxin-containing preparation (designated ADF) from adult T-cell leukaemiaderived cells with interleukin-2-receptor-inducing and growth stimulatory activities for human cells. Rimsky et al. (1986) reported the isolation of a 12 kDa polypeptide preparation from the culture supernatants of an EBV-transformed B-cell line, which displayed interleukin-1-like activi¬ ties in a range of biological assays (Wakasugi et al., 1987) ; this polypeptide was later identified as thioredoxin (Wollman et al., 1988) . The expressed recombinant product had classical thioredoxinlike properties, but no data concerning its possible function in interleukin-1 biological assays were presented. We have found that purified recombinant thioredoxin alone is not active in the rosette inhibition assay, whereas thioredoxin preparations isolated from ovine placental extracts are. This, with the demonstration that the RIT-active principles could be partially resolved from the thioredoxin in the placental preparation, suggests that the activity of the preparation was due to molecules that may bind to thioredoxin and so co-purify with it. The identity of these molecules remains to be established; they may be arachidonic acid metabolites. Such an interpretation would be consistent with data presented elsewhere (Clarke et al., 1990b) showing that metabolites of arachidonic acid, notably the leukotrienes, are active in the rosette inhibition assay. With respect to the thioredoxin preparations of others (Rimsky et al., 1986; Wakasugi et al., 1987) with interleukin-1-like activities, metabolites of the lipoxygenase pathway are increasingly recognized (Farrar & Humes, 1985; Goodwin & Beherns, 1988) as possible second messengers of interleukin-1 action and certain of these metabolites may substitute for interleukin-1 in most biological assays.
As discussed earlier, many studies have tried to define the molecular basis of EPF activity expression by pregnancy serum by attempting to isolate molecules active in the rosette inhibition assay, and many preparations have been reported (Wilson et al., 1983; Cavanagh, 1984 Cavanagh, , 1985 Bose et al., 1989 , Mehta et al., 1989 with the ability to induce increased rosette inhibition titres. These, however, differ remarkably in apparent molecular composition. Our present studies differ from these earlier reports, including that (Wilson et ai, 1983) phenomenon emerges, which in many respects is the antithesis of that which has guided many studies in this field. The common usage of the term EPF has implied the existence in pregnancy serum of a single, unique factor, which has usually been assumed to be a novel, pregnancy-specific protein with the inherent capacity to induce increased RITs. (Cavanagh, 1985; Morton et al., 1987; Bose et al., 1989; Mehta et al., 1989 ). This concept is rendered untenable by the present results.
In seeking to gain an appreciation of the real nature of the EPF phenomenon, it is just as pertinent to ask why non-pregnancy sera do not induce increased RITs as it is to ask why preg¬ nancy sera do. This is so because recent studies (Clarke et al. 1990b ) have revealed that many molecules (arachidonic acid and the leukotrienes, for example) which are normal serum con¬ stituents (Beaubien et al., 1984; Hughes et al., 1989) (Clarke et al., 1990b ) that certain prostaglandins may counteract the action of leukotrienes in inducing increased RITs. While the specific serum moieties responsible for the refractory state remain to be identified, the induction of it is a matter of experimental record, as is its reversal by thioredoxin. Thioredoxin is itself, of course, a widely distributed protein (Rozell et al., 1985) and would also be expected to be a constituent of normal serum (Holmgren & Luthman, 1978; F. M. Clarke, unpublished) . The observed failure of non-pregnancy sera to induce increased RITs implies that the thioredoxin or thioredoxin-related molecules in these sera are in a form, or are rendered to a form, incapable of reversing the refractory state.
Pregnancy sera, like all other sera, would also be expected to contain RIT active moieties, such as the leukotrienes, and they also possess the capacity to induce S2 factor production during the assay procedure, but clearly the refractory state, a consequence of stimulation by all other sera, is either not induced or is rapidly reversed, because cells treated with pregnancy sera do display increased RITs. It is unlikely that pregnancy sera lack the constituents which normally would induce the refractory state. The failure of the anti-thioredoxin-adsorbed pregnancy sera to induce increased RITs and the restoration of this capacity to these adsorbed sera by addition of recombi¬ nant thioredoxin (Fig. 7b) supports the contention that these constituents are indeed present. The observation of increased RITs with pregnancy sera then may imply the presence in these sera of components functionally equivalent to recombinant thioredoxin which reverse or prevent the refractory state. Thus, a distinguishing feature of pregnancy sera could be the presence of functional forms of thioredoxin-related molecules which act in a permissive role in concert with endogenous or induced active moieties to allow the expression of an increased RIT. All other sera may possess non-functional or inhibitable forms of these proteins and so fail to express increased RITs.
The results also suggest that there may be an association between the thioredoxin-related molecules of pregnancy sera and certain of the RIT active moieties in these sera. This possibility arises from considering data from the anti-thioredoxin adsorption experiments (Fig. 7b) , which show that the pH 2 eluates from the solid-phase anti-thioredoxin adsorptions of pregnancy (but not non-pregnancy) sera had the capacity to induce increased RITs. As pure recombinant thioredoxin alone does not display this capacity, one explanation is that the anti-thioredoxin antibodies may have removed certain RIT active moieties which are directly or indirectly associated with the thioredoxin-like proteins of pregnancy sera, just as the isolation protocols applied to placental extracts resulted in the co-isolation of thioredoxin and active moieties. If such an association does exist it may distinguish pregnancy from non-pregnancy sera and may provide the basis for co¬ operative interactions which allow for the presence of functional thioredoxin-like molecules in pregnancy sera, which in turn allow the active moieties in these sera to express their effects in the presence of the otherwise counteracting substances to be found in all sera.
Among the non-pregnancy sera it is obvious that sera obtained from animals in oestrus must represent a special case. While such sera by themselves do not induce the expression of increased RITs, they alone can co-operate with a PAF stimulus to allow for increased RITs (Orozco et ai, 1990 ). In the context of the foregoing discussion, this suggests the presence in these sera of additional or alternative oestrus-specific components which interact with PAF-stimulated, but not serum-or ionophore-stimulated cells (see Clarke et al., 1990a) , to allow the effective generation in the assay of functionally active, thioredoxin-like molecules which reverse the PAF-induced refrac¬ tory state. How this is achieved and how many oestrus-dependent components are involved is not known and certainly no specific mechanism is implied by use of the term 'effective generation'. It could be achieved by some form of activation, by protection against inactivation or by other means. Definition of the molecular mechanism is seen as particularly important as it should go a long way to explaining how the release of embryo-derived PAF in vivo allows for the rapid appearance in maternal serum of the so-called EPF activity so soon after fertilization.
These and other recent studies (Clarke et ai, 1990a, b; Orozco et ai, 1990 ) have begun to identify the molecules and mechanisms at work in the rosette inhibition assay which cause the expression of increased RITs. They have provided new insights into the molecules and mechanisms which allow pregnancy sera to achieve this effect. In so doing, they offer a new model for the EPF phenomenon, which we believe should now assist in the design of further experiments to resolve the many enigmatic properties previously ascribed to the so-called 'early pregnancy factor'.
